Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREBYX versus TIAGABINE HYDROCHLORIDE.
CEREBYX vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant